These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30678050)

  • 41. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
    Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
    Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults.
    LaVoy EC; Bollard CM; Hanley PJ; Blaney JW; O'Connor DP; Bosch JA; Simpson RJ
    Exerc Immunol Rev; 2015; 21():144-53. PubMed ID: 25826370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Wilms tumor gent 1 (WT1)-specific adoptive immunotherapy in hematologic diseases.
    Jiang Y; Lv X; Ge X; Qu H; Zhang Q; Lu K; Lu Y; Xue C; Zhang L; Wang X
    Int Immunopharmacol; 2021 May; 94():107504. PubMed ID: 33657524
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.
    Oka Y; Tsuboi A; Kawakami M; Elisseeva OA; Nakajima H; Udaka K; Kawase I; Oji Y; Sugiyama H
    Curr Med Chem; 2006; 13(20):2345-52. PubMed ID: 16918359
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells.
    Fujiki F; Oka Y; Kawakatsu M; Tsuboi A; Nakajima H; Elisseeva OA; Harada Y; Li Z; Tatsumi N; Kamino E; Shirakata T; Nishida S; Taniguchi Y; Kawase I; Oji Y; Sugiyama H
    Microbiol Immunol; 2008 Dec; 52(12):591-600. PubMed ID: 19120973
    [TBL] [Abstract][Full Text] [Related]  

  • 46. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.
    Sugiyama H
    Jpn J Clin Oncol; 2010 May; 40(5):377-87. PubMed ID: 20395243
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.
    Fujiwara H; Ochi T; Ochi F; Miyazaki Y; Asai H; Narita M; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
    Leukemia; 2015 Dec; 29(12):2393-401. PubMed ID: 26104661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity.
    Falkenburg WJ; Melenhorst JJ; van de Meent M; Kester MG; Hombrink P; Heemskerk MH; Hagedoorn RS; Gostick E; Price DA; Falkenburg JH; Barrett AJ; Jedema I
    J Immunol; 2011 Sep; 187(5):2824-33. PubMed ID: 21821799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
    Oka Y; Tsuboi A; Elisseeva OA; Nakajima H; Fujiki F; Kawakami M; Shirakata T; Nishida S; Hosen N; Oji Y; Kawase I; Sugiyama H
    ScientificWorldJournal; 2007 May; 7():649-65. PubMed ID: 17619750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PRAME peptide-specific CD8
    Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M
    Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
    Kondo K; Fujiki F; Nakajima H; Yatsukawa E; Morimoto S; Tatsumi N; Nishida S; Nakata J; Oka Y; Tsuboi A; Hosen N; Oji Y; Sugiyama H
    J Immunother; 2016 Apr; 39(3):127-39. PubMed ID: 26938946
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.
    Akahori Y; Wang L; Yoneyama M; Seo N; Okumura S; Miyahara Y; Amaishi Y; Okamoto S; Mineno J; Ikeda H; Maki T; Fujiwara H; Akatsuka Y; Kato T; Shiku H
    Blood; 2018 Sep; 132(11):1134-1145. PubMed ID: 30045840
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunotherapy in Acute Leukemias: Implications and Perspectives Using Wt1 Antigen.
    Cebinelli GC; DE Sousa Pereira N; Sena MM; DE Oliveira CE; Fujita TC; DA Rocha SP; DE Abreu Oliveira FJ; Marinello PC; Watanabe MA
    Anticancer Res; 2016 Aug; 36(8):3795-802. PubMed ID: 27466479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.
    Keilholz U; Letsch A; Busse A; Asemissen AM; Bauer S; Blau IW; Hofmann WK; Uharek L; Thiel E; Scheibenbogen C
    Blood; 2009 Jun; 113(26):6541-8. PubMed ID: 19389880
    [TBL] [Abstract][Full Text] [Related]  

  • 55. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
    van Amerongen RA; Hagedoorn RS; Remst DFG; Assendelft DC; van der Steen DM; Wouters AK; van de Meent M; Kester MGD; de Ru AH; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728869
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells.
    Müller L; Knights A; Pawelec G
    Hematol J; 2003; 4(1):57-66. PubMed ID: 12692522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
    Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
    Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HLA-restricted presentation of WT1 tumor antigen in B-lymphoblastoid cell lines established using a maxi-EBV system.
    Kanda T; Ochi T; Fujiwara H; Yasukawa M; Okamoto S; Mineno J; Kuzushima K; Tsurumi T
    Cancer Gene Ther; 2012 Aug; 19(8):566-71. PubMed ID: 22722376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy.
    Kelderman S; Heemskerk B; Fanchi L; Philips D; Toebes M; Kvistborg P; van Buuren MM; van Rooij N; Michels S; Germeroth L; Haanen JB; Schumacher NM
    Eur J Immunol; 2016 Jun; 46(6):1351-60. PubMed ID: 27005018
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.
    Coosemans A; Vergote I; Van Gool SW
    Expert Rev Clin Immunol; 2014 Jun; 10(6):705-11. PubMed ID: 24784346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.